Safety of Janus Kinase Inhibitors: A Real-World Multicenter Retrospective Cohort Study
Authors' conclusion
Our real-world data confirm that JAKis are effective and carry a low risk of AESIs, especially in patients who do not display CV risk factors at baseline.
Study context
- Population
- Patients with rheumatoid arthritis (RA) who ever received 1 JAKi, 4 tertiary care centres in Milan, Italy
- Participants
- 685 patients1,137 patient-years
- Exposure
- BAR vs tofacitinib (TOF) vs UPA vs FIL
- Outcome
- JAKi safety outcomes: major CV events and adverse events of special interest (AESIs: serious and opportunistic infections, VTE, herpes zoster, liver injury, malignancies, deaths)
Methodological detailsmulticentre, real-world
- Multicentre
- Real-world
Main finding
As reported in the abstract
Adverse events of special interest (AESIs)
123
18%
Stroke
1
Deaths, all due to severe infections
3
Observational data: associations, not effects.
Further findings
AESIs in patients with higher cardiovascular (CV) risk (subgroup)
- Frequency of AESIs
- 23%
Differences between Janus kinase inhibitors (JAKis)
- Could not identify differences between JAKis
Safety
- AESIs
- 123 (18%)
- Deaths, all due to severe infections
- 3
- Stroke
- 1
Original publication
Safety of Janus Kinase Inhibitors: A Real-World Multicenter Retrospective Cohort Study. J Rheumatol. Published 1 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →